Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Levodopa-Treated Parkinson's Disease (PRESTO)
NCT00203034Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2000
- Primary completion
- Jan 2003
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rasagiline in Parkinson's disease (PD) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in mean total daily OFF time at 26 weeks. Started May 2000; status: completed.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00203034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00203034.